 V300_crop.jpg){kind=small}
Organovo
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
11555 Sorrento Valley Rd Ste 100, San Di...Phone Number
(858) 224-1000Website
www.organovo.comRevenue
<$5 MillionStock Symbol
ONVOIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
1
1
1
About Organovo
Organovo Holdings, Inc., an early commercial stage company, designs and creates functional and three-dimensional (3D) human tissues for use in medical research and therapeutic applications. The company develops 3D human tissue models through internal development and in collaboration with pharmaceutical, academic, and other partners. Its 3D human tissues could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company offers two commercial products, which include ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing a suite of standardized and 3D human tissues for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion, and drug metabolism and pharmacokinetics; customized human tissues as living, dynamic modeRead more
Organovo Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Organovo your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Organovo recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Organovo
Check if Organovo has recently received funding, and reach out quickly before it becomes old news!
Click to see if Organovo had a recent Job posting/layoffs
Check out if Organovo is spiking on competitors!
Organovo, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Organovo has new funding data
Product Launch: Get notified when Organovo launches new products
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Organovo as Masked Content
Find 2 more new buyers
Compare Similar Companies to Organovo
Compare insights from companies similar to Organovo, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Organovo is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Organovo is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Organovo.
Organovo financials insights
Gather financial insights about Organovo, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Private Equity
$3.5M
2012
Share Placement
$12.8M
2013
Other Financing Round
$7.7M
Stock Offering
$43.3M
2015
Stock Offering
$46M
2016
Stock Offering
$25M
2017
Grant
$1.7M
Organovo Tech Stack
A closer look at the technologies used by Organovo
See more technologies
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Project
Organovo has proposed to amend and restate the Oregon of the Holdings Inc. 2022 Equity Incentive Plan to increase the number of shares reserved for issuance thereunder by 1,775,000 shares.
Compensation & Benefits, Corporate Strategy, Finance, HR Operations, Operations
Project
Organovo has proposed an amendment to its Certificate of Incorporation to allow the Board of Directors to effect a reverse stock split of the company's common stock at a ratio between 1-for-5 and 1-for-20, to be determined by the Board, at any time before November 20, 2025, without reducing the authorized number of shares or requiring further stockholder approval.
Financial Planning, Corporate Strategy, Finance, Financial Strategy
Earnings
Earnings
Financial Planning, Business Development
Organovo News & Media
Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements
SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today reported preliminary unaudited cash for the fiscal year ending March 31, 2025, and net cash utilization results for the fiscal fourth quarter of 2025. The Company expects to release full fiscal second-quarter financial results the week of June 9-13, 202Organovo Provides Business Update
SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today provided a business update.Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company
SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today announced the successful close of the sale of its FXR program, including lead asset FXR314, to Eli Lilly and Company (NYSE:LLY) (“Lilly”). The transaction was completed on March 25, 2025.Organovo Announces Reverse Stock Split
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today announced that it will effect a 1-for-12 reverse stock split of its issued and outstanding common stock that will become effective at 5:00 p.m. Eastern Time on Thursday, March 20, 2025. Organovo’s common stock will commence trading on a reverse stock split-adjusted basis at the
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Organovo
Sign Up For FreeTo access detailed company insights
Organovo Holdings, Inc., an early commercial stage company, designs and creates functional and three-dimensional (3D) human tissues for use in medical research and therapeutic applications. The company develops 3D human tissue models through internal development and in collaboration with pharmaceutical, academic, and other partners. Its 3D human ti... Read More
